92Further, it is necessary to assess whether the net gain arising from the transfers of value by the manufacturer of originator medicines in favour of the manufacturer of generic medicines may be justified, as envisaged in paragraph 86 of the present judgment, by the existence of any quid pro quo or waivers by the manufacturer of generic medicines that are proven and legitimate.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.